Автореферат и диссертация по медицине (14.00.09) на тему:Клиническая эффективность и экономическая обоснованность современной противоастматической терапии у детей

Актуальность темы.

Глава 1. Обзор литературы.

Социальная значимость бронхиальной астмы.

Патогенез бронхиальной астмы.

Существующие подходы к лечению бронхиальной астмы.

Лекарственные препараты, контролирующие течение бронхиальной астмы.

Препараты, облегчающие симптомы бронхиальной астмы.

Длительно действующие р2-агонисты.

Комбинированная терапия ингаляционными глюкортикостероидами и длительно действующими бронхолитиками.

Экономические аспекты оказания медицинской помощи.

ГЛАВА 2 . Материалы и методы исследования.

2.1 Анализ медицинской помощи, оказываемой детям больным бронхиальной астмой.

2.2 Сравнительная эффективность В2-агонистов короткого и длительного действия.

2.3 Сравнение эффективности и безопасности флутиказона пропионата и кромогликата натрия.

2.4 Сравнение эффективности и безопасности флутиказона пропионата в дозе 200 и 400 мкг в сутки.

2.5 Сравнение стоимости/эффективности комбинированной терапии ИГКС и В2-агонистом длительного действия с монотерапией ИГКС в той же и в два раза более высокой дозе.

2.6 Экспертная оценка ассортимента противоастматических лекарственных средств.79 Методы статистического анализа.

ГЛАВА 3. Определение эффективности, безопасности и стоимости противоастматической терапии.

3.1 Определение существующей практики оказания медицинской помощи детям с бронхиальной астмой.

Изучение практики назначения противоастматических препаратов на амбулаторном этапе.

3.2 Сравнительная эффективность В2-агонистов короткого и длительного действия .103 3.3. Сравнение эффективности и безопасности флутиказона пропионата и кромогликата натрия.'.

3.4 Сравнение эффективности и безопасности флутиказона пропионата в дозе 200 и 400 мкг в сутки.

3.5 Изучение стоимость/эффективность комбинированной терапии сальметеролом и флутиказона пропионатом по сравнению с монотерапией ИГКС.

Эффективность лечения в двух возрастных группах.

Стоимость/эффективность лечения комбинированной терапией по сравнению с монотерапией ИГКС.

3.6 Экспертные оценки современной противоастматической терапии.

Глава 4. Клинико - организационные алгоритмы оказания медицинской помощи детям с бронхиальной астмой.

1. Абелевич М.М, Яновер Л.Г., Тарасова A.A. и др. Особенности клинического течения бронхиальной астмы у детей при летальных исходах. Сб. тез.: 6 Нац. конгресс по бол. орг. дыхания. Новосибирск. - 1996. - С. 6

2. Аветисян М.М., Кобзарь Л.В. Маркетинговые исследования ассортимента препаратов для лечения бронхиальной астмы. //Атмосфера. Пульмонология и аллергология. 2002. - Т. 3, № (6). - С. 42-44.

3. Балаболкин И.И., Ефимова A.A. Влияние экологических факторов на распространенность и течение аллергических болезней у детей.// Иммунология. -1991. -№ 4-С. 34-37

4. Балаболкин И.И. Бронхиальная астма у детей. М., 2003

5. Белопасова H.A., Силищева H.H. Структура и динамика БА у детей Астраханской области. Медико-социальные аспекты здоровья и медицинского обслуживания населения. Сб.статей. Астрахань, 1998 т.13. - с.16-18.

6. Беляевский И.К. Маркетинговое исследование: информация, анализ, прогноз. -М.: Финансы и статистика, 2001. С. 320

7. Бронхиальная астма. Глобальная стратегия.//Всемирный доклад института Сердце, легкие, Кровь и Всемирной организации здравоохранения. М., - 1996.-С.16

8. Важенин A.A., Ортенберг Э.А., Кислицина H.A., Близнякова Е.В. Разработка стандартов лекарственного обеспечения клинической больницы в системе ОМС. Тезисы научно-практической конференции Проблемы стандартизации в здравоохранении. Москва, 1999. С.36-37

9. Всемирная организация здравоохранения (ВОЗ). 2000. Statistics database. http://www.who.int/whosis/statistics Revised January 2000.

10. Вялков А.И, Катлинский A.B., Воробьев П. А. Стандартизация, фармакоэкономика и система рационального лекарственного обеспечения населения. Проблемы стандартизации в здравоохранении. 2000. - №4. С. 3-6

11. Гельцер Б.И., Просекова Е.В., Матвеева H.H. Распространенность БА среди детей г. Владивостока, стандартные исследования ISAAC// Тихоокеанский медицинский журнал. 2000. - №4. - С.29-31.

12. Геппе H.A. Детская астма: главное слагаемое успеха партнерство врача, больного, родителей. //Медицинский курьер. - 1998- Т. 5, № 11.- С.60

13. Геппе H.A., Каганов С.Ю. Задачи лечения бронхиальной астмы у детей. //Русский педиатрический журнал. 1999. -№ 4. - С. 35-37

14. Геппе H.A., Каганов С.Ю. Национальная программа "Бронхиальная астма у детей. Стратегия лечения и профилактика'7/Российский педиатрический журнал. -1998.- №2. С.8-12

15. Геппе H.A., Колосова Н.Г., Бунатян А.Ф., Ильин А.Г., Беда М.В., Медникова О.Б. Дифференцированный подход к назначению ингаляционных кортикостероидных препаратов при бронхиальной астме у детей. //Пульмонология. 1999. -№ 2. - С. 26-28

16. Геппе H.A., Новикова A.B., Сосюра В.Х, Карпушкина A.B. Характер эндобронхита у детей с тяжелым течением бронхиальной астмы и тактика лечения.// Тезисы 7 Национального конгресса по болезням органов дыхания, Москва. 1997. А 232.

17. Глобальная стратегия лечения и профилактики бронхиальной астмы. Национальные институты здоровья США Национальный институт сердца, легких и крови. Пересмотр 2002 г. М., Атмосфера, 2002.

18. Голубков Е.П. Маркетинг: Словарь-справочник. М.: Дело, 2001.- С. 440

19. Горелов А.И., Придаткина Н.Г., Лечение обострений Б.А. пульмикортом с помощью небулайзера /Тезисы 11 Национального конгресса по болезням органов дыхания, Москва, 2001 г. М.: Универсум Паблишинг, 2001. - С. 23.

20. Горячкина JI.А., Ненашева Н.М., Терехова Е.П. Эффективность отечественного препарата будесонид в комплексной терапии бронхиальной астмы. Тезисы 5 Национального конгресса по болезням органов дыхания. 1995. АЗЗ

21. Дмитрюк Т.М., Зырянов С.К., Насыров Х.М. Разработка программы использования лекарственных средств в республике Башкортостан. Тезисы 12 Национального конгресса по болезням органов дыхания, 2002- с.751-752

22. Думпэ С. «Дышать право каждого» // Фармацевтический Вестник, приложение Поволжье. - 2000, июнь. - С.З.

23. Жаков Я.И., Мицкевич С.Э. Клинико-эпидемиологические исследования детской БА на Южном Урале/Актуальные проблемы медицинской науки и проф.образ. Труды научной сессии. Челябинск, 2000. С. 105-108.

24. Евланов Л.Г., Кутузов В.А. Экспертные оценки в управлении. М.: Экономика, 1978.-С. 133.

25. ЗО.Здитовецкая H.A. Респираторная карта Москвы / Автореф. дисс.канд.мед.наук. -М., 1998. 24с.

26. Ильина Н.И., Хаитов P.M. Эпидемия аллергии, астмы в чем причина? // Астма. -2001.- том 2., №1. - С.35.

27. Здоровье населения России и деятельность учреждений здравоохранения в 1997 году. Статистические материалы МЗ РФ. М., 1998.

28. Здоровье населения России и деятельность учреждений здравоохранения в 1998 году. Статистические материалы МЗ РФ. -М., 1999.

29. Здоровье населения России и деятельность учреждений здравоохранения в 1999 году. Статистические материалы МЗ РФ. М., 2000.

30. Зырянов С.К., Фармакоэпидемиология вчера, сегодня, завтра. //Фапматека. 2003.-№3.-С. 13-17

31. Каганов С.Ю., Геппе H.A. Перспективы Национальной программы «Бронхиальная астма у детей: стратегия лечения и профилактика» //Пульмонология. 1999. -№1 - С. 26-28

32. Капустина Н.Р., Распространенность и факторы риска развития БА у детей Удмуртии / Автореф.дисс.к.м.н. Ижевск, 2000. - с.23.

33. Карташова Н.В., Малышева И.Е. Эпидемиология бронхиальной астмы в Санкт-Петербурге / Тезисы докладов Международного конгресса по болезням органов дыхания. -М.: Универсум Паблишинг, 1998.-c.474.

34. Кобзарь JI.B., Аветисян М.М. Характеристика рынка лекарственных препаратов для лечения бронхиальной астмы.// Фармация. — 2001. №4. - С.7-10

35. Кондюрина Е.Г., Елкина Т.Н., Филатова Т.А., Гавалов С.М. Возрастные аспекты эпидемиологии БА у детей г.Новосибирска // Пульмонология. 1998.-№1.-С.38-43.

36. Кондюрина Е.Г. Факторы риска и патогенетические особенности течения БА у детей в макро- и микроэкологических условиях города Новосибирска / Дисс.д.м.и., Новосибирск, 1999. 378 с.

37. Коростовцев Д.С., Макарова И.В. Смертность при бронхиальной астме у детей. Материалы по Санкт-Петербургу за 24 года // Аллергология. 1999. - №1. - с.19-25.

38. Крымский С.Б., Жилин Б.Б., Паниотто В.И. и др. Экспертные оценки в социологических исследованиях. Киев: Наукова думка, 1990. -320с.

39. Леонова М.В, Белоусов Д.Ю. Первое российское фармакоэпидемиологическое исследование артериальной гипертонии. //Качественная клиническая практика. 2002 №3 - стр.47-53

40. Лещенко И.В., Чирков В.И., Лившиц A.A. Эпидемиология бронхиальной астмы в крупном промышленном регионе. //Тер. Архив . 1998 - №12. - С. 41-43

41. Лобов Е.Б., Литвищенко Ю.Ф. Фармкоэпидемиологические исследования в психиатрии. Сообщение 2. Качественный фамакоэпиемиологический анализ: обзор.//Соц и клинич. Психиатрия 2000.- Т.10, №4. - 98-107

42. Лусс Л.В., Богова A.B., Ильина Н.И. Новые индустриальные технологии и астма. // Астма. 2001. - том 2. - №1. - с.44-46.

43. Лысикова И.В. Распространенность аллергических заболеваний у детей по результатам мультицентровых исследований в рамках международной программы

44. AAC / Гос.нацучный центр Ин-та Иммунологии МЗ РФ, Автореф.дисс.к.м.н., М., 1999, с.20.

45. Лютина Е.И., Курилова Т.Н., Манеров Ф.К.,Эпидемиология БА у детей Новокузнецка / Пульмонология (приложение). Национальный конгресс по болезням органов дыхания, Москва, 2001 г, сборник резюме. М.: Универсум Паблишинг, 2001,- с.350.

46. Министерство здравоохранения 1998 А. Государственный отчет о состоянии здоровья населения в Российской Федерации в 1997. Москва

47. Национальная программа "Бронхиальная астма у детей. Стратегия лечения и профилактика" Москва. 1997

48. Неотложная терапия бронхиальной астмы у детей. Пособие для врачей. /Ред. Баранова A.A. Москва 1999.

49. Нестеров В.А. Статистика инвалидности. М. 1997

50. Петров В.И., Смоленов И.В., Пономарева Ю.В. и др. Оптимизация терапии тяжелой бронхиальной астмы у детей с позиции анализа «затраты/эффективность. //Аллергология 2003. - №1. -С. 3-8.

51. Петров В.И., Фармкоэпидемиология и фармакоэкономика в России: состояние, проблемы и переспективы развития. //Клин. Исслед. Лекарств в России. 2002.-№1. - С. 8-10

52. Пономарева Ю.В. Оптимизация применения лекарственных средств для лечения тяжелой бронхиальной астмы у детей (фармакоэкономическое исследование) / Автореф. Кан. Мед.наук Волгоград 2002.

53. Резник И.Б., Щербина А.Ю., Кулак A.B. и др. Особенности воспаления при бронхиальной астме у детей //Педиатрия. 1997. -№2. -С.153-158

54. Российский статистический ежегодник, 2001 / М.: Госкомстат.- 2002.

55. Смирнов H.A., Смоленов И.В. Бронхиальная астма в Центральной и Восточной Европе: представления больных и реальная клиническая практика (результаты исследования AIR CEE).// Аллергология 2001. - №4. - С. 3-9

56. Смирнова М.С., Кузнецов А.Н. Тенденции эпидемиологии БА в нижегородской области / Пульмонология (приложение). Национальный конгресс по болезням органов дыхания, Москва, 9 2001 г, сборник резюме. М.: Универсум Паблишинг, 2001.- с.352.

57. Солдатов Д.Г., Авдеев С.Н., Кусакина И.А. Ретроспективный анализ эпидемий БА // Пульмонология. 1996. - №4. - С.84.

58. Ушаков В.В., Калугина Л.И., Мирозоян М.Г. Клинико-экономическое изучение шизофрении: методология исследования и сравнительный анализ стоимостных затрат в стационарной и амбулаторной сети// Журн. Невропат и психиатр. -1990-т.90. С.114-117

59. Федосеева Л.С., Купаев. В.И., Буцык Н.В., Сенкевич Н.Ю. Контроль бронхиальной астмы в амбулаторных условиях //Пульмонология. 2002. - №5. - С. 72-75

60. Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины. Пер с англ. М.: Медиасфера, 1998

61. Чайковская М.В. Клинико-эпидемиологическая характеристика аллергических заболеваний у детей Тюменского региона / Автореферат дисс.к.м.н., Тюмень, 1997, 193с.

62. Черняк Б.А., Буйнова С.Н., Тяренкова C.B. Эпидемиология БА в Иркутской области/ Сб.тр.: Современные проблемы аллергологии, клинической иммунологии и иммунофармакологии. Иркутск, 2000

63. Черныш Е.А. Прогнозирование и планирование в условиях рынка.- М.: ПРИОР, 2000.- 176 с.

64. Чучалин А.Г. Бронхиальная астма. М.: Агар, 1997

65. Чучалин А.Г. Стратегия и профилактика бронхиальной астмы в России. //Intern. J Immunorehabil. 1997. № 7. - С 51-56.

66. Чучалин А.Г., Смоленов И.В., Огородова JI.M. и др. Фармакоэпидемиология детской астмы: результаты многоцентрового Российского ретроспективного исследования (ФЭДА-2000). //Пульмонология 2001. Приложение

67. Чучалин А.Г., Черняк Б.А, Медникова Р.Б., Беда М.В. Эффективность сочетанного применения флютиказона пропионата и сальметерола при 18-месячной терапии больных стероидозависимой бронхиальной астмой. //Пульмонология.-1998.-№3,-С. 64-70.

68. Шевченко Ю.Л. Об итогах хода реформ и задачах по развитию здравоохранения и медицинской науки в Российской Федерации на 2000-2004 годы и на период до 2010 года, http://vmw.mednet.ru/urgent.htm

69. Шепин В., Семенов Ю., Шейман И. Реформа системы здравоохранения в России. 1992 O.P.York.

70. Шишкин С. Проблемы реформирования Россиской системы здравоохрарнеия //Eurohealth. 1997. V.4, № 6,- Р 59-64

71. Aalbers R., Kauffman HK., Groen H. et all. The effect of nedcomil sodium on the early and late reaction and allergen-induced bronchial hyperrsponsiveness.//J Allergy Clin Immunol. 1991.- Vol. 87(5): - P. 993-1001.

72. Abbinante-Nissen J. M., Simpson L. G., Leikauf G. D. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. //Am. J. Physiol. 1995. - Vol. 12 - L601-606.

73. Abel-Smith B. An Introduction to health. Policy, Planning and Financing. Prenitice Hall. London. 1994

74. Aberg N. Asthma and allergic rhinitis in Swedish conscriptions. //Clin.Exp.Allergy. -1989. -Vol. 19. -P 59-63

75. Aberg N., Sundell J., Eriksson B. Prevalence of allergic diseases in schoolchildren in relation to family history, upper respiratory infections and residential charactristics. //Allergy. 1996. - Vol. 51. - P.232-237

76. Adams N, Bestall JM, Jones PW. Inhaled fluticasone at different doses for chronic asthma (Cochrane review). In: The Cochrane Library, Issue 1. Oxford: Update Software,. 2002.

77. Adcock I.M., Barnes P. J. Ligand-induced differentiation.of glucocorticoid receptor (GR) transrepression and transactivation (abstract). //Am. J. Respir. Crit. Care Med. 1996. -Vol. 153-P. A243

78. Adcock I.M:, Brown C. R., Gelder C. M. et al. Effects of glucocorticoids on' transcription factor activation in human peripheral blood mononuclear cells. //Am. J. Physiol. 1995. - Vol. 268. - C331-C338

79. Adcock I. M:, Peters M., Gelder C. M. et al. Increased tachykinin receptor gene expression in asthmatic lung and its modulation by steroids. //J. Mol: Endocrinol. 1993. -Vol. 11.-P. 1-7

80. Adebrouth E., Rosenchall L., Glennow C. High-dose inhaled budesonide in the treatment of severe steroid-dependent asthmatics. //Allergy -1985. Vol. 40. - P.58-64

81. Adelhort E, Tompson S. Advantages of high-dose inhaled budesonide.// Lancet 1988. Vol. 1 (8583) - P. 476

82. Agertoft L., Pedersen. S. A randomized double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. //J. Allergy Clin. Immunol 1997.- Vol. 99. - P. 773-780.

83. Agertoft L., Pedersen S. Bone densitometry in children treated for 3-6 years with high dose inhaled budesonide.// Eur. Respir. J-1993- Vol. 6(Suppl. 17): P. 261S.

84. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. //Resp.Med. 1994. - Vol*. 88. -P. 373-381

85. Allen D.B. Systemic effects of inhaled corticosteroids in children. //Curr Opin Pediatr. 2004 - Vol. 16(4) - P. 440-4.

86. Allen S.C., Prior A. What determines whether an elderly patient can use a metered dose inhaler correctly? //Br J Dis Chest 1986.- Vol. 80.- P. 45-9

87. Altounyan* R.E.C., Cole M., Lee T.B. Inhibition of sulfur dioxide-induced bronchoconstriction by nedocromil sodium and' sodium cromogligate in non-asthmatic, atopic subjects.// Eur. J. Respir.Dis.- 1986. Vol. 69 (Suppl 147) - P. 274-276

88. Andarae S., Axelson O., Bjorksten B. et all. Symptoms of bronchialhyperreactivity and asthma relation to environmental factors.// Arch.Dis.Child. 1988.- Vol.63, - p.473-478

89. Anderson GP Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator.// Life Sciences 1993- Vol.52. - P. 2145-2160

90. Andersson F, Stahl E, Barnes PJ et al. Adding formoterol to budesonide in moderate asthma health economic results from the FACET study.// Resp Med 2001; Vol. 95.- P. 504-512

91. Andersson P., Ryrteldt A. Boitransformation of the topical glucocorticoids budesonide and beclomathasone 17a,21-dipropionar in human liver and lung homogenate.//J.Pharmacool.- 1984 Vol.36 - P.763-765

92. Anenden V, Egemba G Kessel B et al Salmeterol facilitation of fluticasone-induced apoptosis in eosinophils of asthmatics pre- and post-antigen challenge. //Eur Resp J.- 1998.-Vol. 12-P. 157s

93. Applied Therapeutics: The clinical use of drugs. 6 th ed. Young LY, Koda-Kimbe MA (eds) Vancouver. 1995

94. Armenio L., Baldini C., Badare M. et all. Double-blind, placebo controlled study of the efficacy of nedocromil sodium in asthma. //Arch.Dis.Child. 1993. - Vol. 68. - P. 193-187

95. Armitage R.J, Fanslow W.C., Stockbine L. et all. Molecular and biological characterisation of a murine ligand for CD40.//Nature. 1992,- Vol. 357.- P. 80-82

96. Armour C.L., Johnson P.R.A., Black J.L. Nedocromil sodium inhbits substance P-induced potentiation of cholinergic neural responses in the isolated innervated rabbit trachea.//J Pharmacol 1991:-Vol. 11:-N 1-P. 67-72.

97. Audit commission. A prescription for improvement: towards rational prescribing in general practice. London: HMSO, 1994

98. Auty RM, Clarke AJ. Kinetics and disposition of Nedocromil sodium in man: a preliminary report. //Eur. J.Resp.Dis. 1986. - Vol. 69 (Suppl.147), - p.246-247

99. Avery AJ, Rodgers S, Heron T et al. A prescription for improvement? An observational study to identify how general practices vary in their growth in prescribing cost.//BMJ 2000 - Vol. 321 - P. 276-281

100. Avital A., Springer C., Bar-Yishay E., Godfrey S. Adenosine methacholine and exercise challenges in children with asthma or paediatric chronic obstructive pulmonary disease. //Thorax -1995. Vol.50: - p.511-6.

101. Baraniuc J.N., Ali M., Brody D. et al Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. //Am J Respir Crit Care Med 1997.-Vol. 155.-P. 704-710.

102. Barber J.A., Thompson S.G. Analysis and interpretation of cost data in randomised controlled trials: review of published studies. //BMJ 1998. - Vol. 317.- P. 1195-1200

103. Barnes N., Hallett C., Harris T.A. An overview of morning peak expiratory flow rate (PEFR) for clinical trials comparing fluticasone propionate (FP) with budesonide (BUD)//Eur. Respir. J. 1996. - Vol.9 (Suppl. 23) - 52s-53s.

104. Barnes P. J. Inhaled glucocorticoids: new developments relevant to updating the Asthma Management Guidelines.//Respir. Med. 1996.- Vol. 90.- P. 379-384.

105. Barnes P.J. Neural control of the airways in health and disease. //Am Rev Respir Dis- 1986,-Vol. 134.-P. 1289-314.

106. Barnes P. J. Mechanism of action of glucocorticoids in asthma.// Am. J. Respir. Crit. Care Med. 1996. - Vol. 154.- P. S21-S27

107. Barnes P. J., Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. //Trends Pharmacol. Sci.- 1993.- Vol. 14,- P. 436-441

108. Barnes P. J., Adcock I. M. NFB: a pivotal role in asthma and a new target for therapy.//Trends Pharmacol. Sci. 1997. - Vol. 18.-P. 46-50

109. Barnes P.J., Baraniuk J., Belvisi M.G. Neuropeptides in the respiratory tract. //Am Rev Respir Dis 1991. - Vol.144.- P. 1391-9.

110. Barnes P. J., Chung K.F. Questions about inhaled beta-2-agonisten asthma// Trends Pharmacol. Sci.- 1992. Vol. 13 (1)- P. 20-23

111. Barnes PJ, Holgate ST. Asthma mechanisms, determinants of severity and. treatment the role of nedocromil sodium. //Clin. Exp.Allergy. 1995. - Vol.25. - P. 77187

112. Barnes PJ, Pauwels RA Theophylline in the management of asthma: time for reappraisal?// Eur Resp J 1994. - Vol. 7.- P. 579-91

113. Barnes P.J., Pederson S., Busse W. Efficacy and safety of inhaled corticosteroids new developments.// Respir. Crit. Care Med 1998 - Vol. 157(3). - P. S1-S53

114. Bateman E.D., Britton M., Carrillo J. et al. Salmeterol/Fluticasone (50/100 mg) Combination Inhaler. A new effective and well tolerated treatment for asthma. //Clinical Drug Investigation 1998.-Vol. 16(3).-P.193-201

115. Battisini E, Gianiorio P., Girosini D. et all. Bronchial asthma in infancy and childhood.//Eur. Respir. Rev. 1993,- Vol. 3. -P. 373-6

116. Beauvais F, Heibolt C, Benveniste J. Effect of sodium cromoglycate and nedocromil sodium on anti-IgE-induced and anti-IgG4-induced basophil degranulation. //Drugs. 1989. -Vol. 37 (Suppl 1).- P. 4-8

117. Begaud B., Dangoumau J. Pharmacoepidemiology: definition, problems, methodology.// Therapie 2000- Vol. -55 (Suppl 1). - P. 113-7

118. Belcher N.G., Murdoch R.D., Dalton N. et al. A comparison of mediator and catecholamine release between exercise and hypertonic saline-induced asthma.// Am Rev Respir Dis 1988:- Vol. 137.- P. 1026-32

119. Bergmann K.C., Bauer C.P., Overlack A. A placebo-controlled blinded comparison of nedocromil sodium and beclomethasone dipropionate in bronchial asthma. //Lung 1990:1- Vol. 68- Suppl:230-9.

120. Bestall J.C., Adams N.P., Jones P.W. Reliability and responses of therapeutic outcomes used in trials of inhaled steroids in asthma.// Am J Respir Crit Care 2000; -Vol. 161.- P. A315

121. Billings J., Zeitel L., Lukomnik J. et al. Impact of socio-economic status on hospital use in New York City. //Health for All (Millwood) 1993; Vol. 12 (1) - P. 16273

122. Bisgaard H. Cost-effectiveness of Fluticasone pripionate Administered Via Metered-Dose Inhaler Plus Babyhaler Spacer in the treatment of Asthma in Preschool-Aged Children// Chest 2001 - Vol.120. -P. 1835-1842.

123. Bisgaard H. Adrenal function in children with bronchial asthma treated with beclomethasone propionate or budesonide.// J Allergy Clin Immunol 1988. - Vol. 81. -P.1088-95

124. Bisgaard H., Allen D., Malinowski J. et al. Safety and efficacy 12 month treatment with inhaled fluticasone propionate in children aged 1 to 4 years old with recurrent wheezing.// Eur.Respir.J 2002; - Vol. 20 (Suppl 38)- P. 219s, 1444

125. Bisgaard H., Gillies J., Groenewald M., Maden C. et al. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study.//Am J Crit Care 1999; - Vol. 160.-P. 126-131

126. Black D. An Anthology of False Antitheses. Nuffield Provincial Trust, London 1984.

127. Blainey D. Cost of acute asthma how much is preventable? //Health Trends 1990,-Vol. 22.-P. 151-153

128. Bleeker E.R., Rechsteiner E., Mason P.L., Meyers D.A. Effect of two doses of nedocromil sodium on the immediate response to inhaled ragweed allergen.// Am Rev Respir Dis- 1990.- Vol. 141(4,pt2):- A 656 (abstract).

129. Bloom J.W., Meisfeld R.L. Molecular mechanisms of glucocorticoid action. In.Szefler SJ, Leung DYM, eds Severe Asthma. New York: Marcel Dekker. 1992.- P. 255-84

130. Boe J., Rosenthall L., Alton M., et al. Comparison of dose-response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma. //Allergy 1989; Vol. 44.- 349-55.

131. Boggs D.F., Bartlett D. Chemical specificity of laryngeal apneic reflex in puppies. //J Appl Physion 1982: - Vol.53:- p. 455-62.

132. Bolton M.B., Tilley B.C., Kuder J. et al. The cost and effectiveness of an education program for adults who have asthma. //J Gen Intern Med 1991; - Vol. 6.- P. 401-7

133. Bone M.F., Kubik M.M., Keany N.P. et al. Nedocromil sodium in adults with asthma dependent on inhaled corticosteroids: a double-blind, placebo controlled study. // Thorax. 1989.- Vol. 44. - P. 654-659

134. Bootsma G.P., Dekhuijzen P.N., Festen J. et al. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. //Am. J. Respir. Crit. Care Med. 1996.- Vol. 153.- P. 924-930

135. Bordet R., Gautier S., Le Louet H. et al. Analysis of direct cost of adverse drug reactions in hospitalized patients. //Eur J Clin Pharmacol 2001. - Vol. 56 (supppl.12). -P. 935-41

136. Borish, L., Aarons A., Rumbyrt J., et al. Interleukin-10 regulation in normal subjects and patients with asthma. J. Allergy Clin. Immunol.- 1996. Vol. 97.- P. 12881296

137. Borson D. B., Jew S., Gruenert D. C. Glucocorticoids induce neutral endopeptidase in transformed human trachea epithelial cells. //Am. J. Physiol -1991. Vol. 260.- P. L83-L89

138. Boulet LP Long- versus short-acting beta 2-agonists. Implications for drug therapy. //Drugs. 1994.- Vol. 47. P. 207-222

139. Bouquet J, Jeffery P. K., Busse W. W et al Asthma. From Bronchoconstriction to Airways Inflammation and Remodeling. //Am J Respir Crit Care Med 2000. - Vol. 161.-P. 1720-1745

140. Bouspuet J., Chanez P., Lacoste JY. et al. F.B. Eosinophilic inflammation in asthma. //N Engl J Med 1990.- Vol.323.- P. 1033-9

141. Bouspuet J., Emost A, Germoutz J et al. Double-blind multicentre study of cetirizine in grass polen-induced asthma.// Ann.Allergy 1990. -Vol.65: -p.504-8

142. Bradding P., Roberts JA., Britten KM. et al. Iinterleukin-4, 5, 6 and TN Fa in normal and asthmatic airways; evidence for the human mast cell as an important source of these cytokines. //Am J Respir Cell Mol Biol -1994. Vol. 104- p.71-80.

143. Bremner P., Woodman K. Burgess C. et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol.// Eur Respir J. 1993 -Vol. 6(2).-P. 204-10.

144. Brillman J.C., Tanberg D. Observation unit impact on ED admission for asthma// Am J Emerg Med 1994; - Vol. 12 (1).- P. 11-4

145. Brocklebank D., Wright J., Cates C. Systematic review of clinical effectiveness of pressurized metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma// BMJ 2001; - Vol. 323 - P. 896

146. Brodgen R.N., Faulds D. Salmeterol xinofate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.// Drug. -1991.-Vol.42.-P. 895-912

147. Brogden R.N., Speight T.A., Avery G.S. Sodium cromoglycate: A review of its mode of action, pharmacology, therapeutic efficacy and use.//Drugs. -1974;- Vol.7 ( 3-4).- P.162-282

148. Broide D., Gleich G., Cuomo A. et all. Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. //J.Allergy Clin Immunol -1991- Vol. 88.- P. 637-48.

149. Brown K, Neale M.G., Auty R.M. et al. The pharmacokinetics of sodium crmoglicate. In: Kerr J.W. and Ganderton M.A. (eds). Proc.XlInternat.Con.Allergy.Clin.Immunol.London. 1982.- P. 513-516

150. Brown P.J., Greville H.W., Finucane K.E. Asthma and irreversible airflow obstruction.//Thorax 1984; Vol. 39.- P. 131-6

151. Bruijnzeel P.L.B., Warringa P.A.J., Kok P.T.M. Inhibition of neutrophil and eosiniphil induced chemotaxis by nedocromil sodium and sodium cromogligate// Br. J. Pharmacol. 1990, - Vol.99, - P.798-802

152. Bukantz S.C., Lockey R.F. IgE immediate hypersensitivity. In Weiss EB, Stein M eds. Bronchial asthma. Mechanisms and therapeutics. Boston: Little, Brown; 1993, p.68-79

153. Boulet L.P. Asthma education: what has been its impact?// Can Resp J 1998; -Vol. 5 (suppl A). - P. 91A-96A

154. Burger E. J. Field M. From Assurance to Insurance in Russian Health Care: The Problematic Transition// American Journal of Public Health. 1998 Vol. 88(5).- P. 755758

155. Burr M., Butland B., King S. Changes in asthma prevalence: two surveys 15 years apart.//Arch. Dic.Child. 1989.- Vol.64.- P. 1452-56

156. Businco L, Cantani A., Di Fasio A, Bernardini L. A double-blind placebo-controlled study to assess the efficacy of nedocromil sodium in the manengment of childhood grass-pollen asthma.//Clin.Exp.Allergy. 1990.- Vol.20.- P. 683-688

157. Busse W., Raphael GD., Galant S. et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial.// J Allergy Clin Immunol 2001; - Vol. 101.- P. 461-468

158. Calhoun W.J. Sedgwick J.B., Jarjour N. et al. The effect of mast cell activation on eosinophil recruitment lo the airways after antigen challenge. //Am Rev Respir Dis — 1993.-Vol. 14714 (Pt 2): A241 (abstract).

159. Canadian Antimicrobial Study Group. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis.// J Antimicrob Chemother. 1999; - Vol. 43 -Suppl A:- P. 25-30.

160. Cargill K., Ind P.W., Thawaites R.M.A. The cost of asthma exacerbation.// Eur. Resp. J.- 1999.- 14 Suppl. -Vol. 30 381 s

161. Carlsen K-II. Epidemiology of childhood asthma. //Eur. Respir.Rev. -1994. -Vol. 4(17). -P. 5-9

162. Cates C. Chronic asthma. Extract from "Clinical Evidence". //BMJ 2001; - Vol. 323.- P. 976-979

163. Cavallo A., Cassaniti C., Clogger A. Action of nedocromil sodium exersize-asthma in adolescents.// J. Investig.LAllergol.Clin.Immunol.- 1995. -Vol. 5(5). -P. 286288

164. Centre for Disease Control and Prevention. Asthma United States, 1982-1992. Morbid Mortal Wkly rep 1995; - Vol. 43 (1-52).- P. 952-5

165. Cerveri I, Locatelli F, Zoia MC et al. International variations in asthma treatment compliance: the results of the European Community Respiratory Health Survey.// Eur Resp J 1999; - Vol. 14.- P. 288-294

166. Chung F., Fabbri L.M. Asthma European Respiratory Monograph. 2003. - V. 8; Monograph 23, - P. 278-293

167. Chang K., Nach D. The role of pharmacoecomonic evaluations in disease management.//Pharmacoeconomics 1998. - Vol.14. - P. 11-17

168. Chervinsky P., van As A., Bronsky E.A. et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. // J. Allergy Clin. Immunol. 1994.- Vol. 94.- P. 676-683

169. Cirule I., Mehra S., Kamin W., et al. The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms.// Eur.Respir.J -2002 Vol.20 (Suppl 38), 219s, - P. 1446

170. Clark N.M., Feldman C.H., Evans D. et al. The impact of health education of frequency an coct of haelth care use by low income children with asthma.// J Allergy Clin Immunol 1986;-Vol. 78 (iPt 1).-P. 108-15

171. Clarke S.W., Newman S.P., Therapeutic aerosols. 2. Drugs available by the inhaled route (editorial).// Thorax. -1984. -Vol.39. -P. 1-7

172. Coleridge H.M., Coleridge J.C.G. Afferent nerves in the airways. In: Barnes PJ. Ed. Autonomic control of the respiratory system. London : Harwood. 1994.

173. Collins S. M., Caron G., Lefkowitz R. J. ß-Adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids.// J. Biol. Chem. 1988. -Vol. 263.-P. 9067-907

174. Condemi J., Pierantoni W.N., Wald J. Use of different spacer with Nedocromil sodium: comparative improvement in taste. //Ann.Allergy. -1994. Vol. 26- P. 59-60

175. Condemi J., Goldstein S., Kalberg C. et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. //Ann. Allergy Asthma Immunol. -1999.- Vol. 82 -P. 383-398

176. Connett G.L., Lenney W., McConchie S.M. The cost-effectiveness of budesonide in severe asthmatics aged one to three years.// Br J Med Econ 1993; Vol. 6.- P. 127-34

177. Crain E.F, Weiss K.B., Fagan M.J. Paediatric Asthma care in the US emergency department: current practice in the context of the National Institutes of Health guidelines.//Arch Pediatr Adolesc Med 1995; - Vol. 149 (8).-P. 893-901

178. Creticos P., Norman P., Burk J. et al. The use of twice daily nedocromil sodium in the treatment of asthma. //J Allergy Clin Immunol. 1995- Vol. 95- P. 829-36.

179. Crimi E., Prefice U., De Benedetto F. et all. Nedocromil sodium versus theophylline in the treatment of reversible obstructive airways diseases. //Ann. Allergy, Asthma. Immunol. -1995. -Vol.74 (6).-P. 501-508

180. Crimi N., Palermo F., Oliveri R. et all. Comparative study of the effects of Nedocromil sodium (4mg) and sodium cromogligate (10mg) on adenosine-induced bronchconstriction in asthmatic subjects// Clin.Allergy. -1988. -Vol.18. -P. 367-374

181. Crimi N., Palermo F., Oliveri R. et all. Effect of sodium cromogligate and nedocromil sodium on bronchospasm induced by inhaled Substance P// Abstracts of the 6 th Congress of the Eur.Soc.Pneumology.- 1987- A 505.- P. 48

182. Crompton G.K. Problems patients have using pressurized aerosol inhalers.// Eur J Resp Dis 1982; Vol. 63 (Suppl. 119).- P. 101-4

183. Cserhati E., Barouni M., Meezei G. Data on the late prognosis of pediatric asthma.//Schweiz. Med. Wochen. -1991. -Vol. 121 (Suppl.40).- P. 29

184. Curtis S., Petukhova N., Taket A. Health care reforms in Russia: the example of St Petersburg.// Social Science & Medicine. 1995 - Vol. 40(6).- P. 755-65.

185. Delia Cioppa F., Kisilev P., Matos D. et al. Four times albuterol worsens peak flow variability in asthma whereas twice daily formoterol does not. Am J Resp Crit Care Med- 1997-Vol. 155,-N4,- A341

186. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. //Resp.Med. -1997. -Vol.91 (Suppl.A). -P. 22-28

187. Devalia J.L., Sapsfor RJ., Rusznak C., Davies R.J. The effect of human eosinophils on cultured human nasal epithelial cell activity and the influence of nedocromil1 sodium. // Am J Respir Cell Mol Biol -1992.- Vol. 7- P. 270-7.

188. Dixon C.M., Barnes P.J. Bradykinin induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate. //Br J Pharmacol -1989.- Vol.27- P. 831-6.

189. Dixon C.M.S, Ind P.W. Inhaled sodium metabisulphate induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate.// Br J Clin Pharmacol 1990.- Vol.30.- P. 371-6.

190. Dolovich M., Ruffino R., Corr D. et all. Clinical evaluation of a simple demand inhalation MDI aerosol delivery device.// Chest.-1983 -Vol. 84 -P. 36-41

191. Doneely A., Bernstein D.I, Goldstein'S. et al. Speed of onset of action Tilarin. //Allergy.- 1996.-Vol.51 (28 Suppl).-P. 14-9^

192. Doull J., Freezer N., Holgate S. Growth of pubertal children with mild asthma treayed with inhaled beclomethasone dipropionate. //Am J Respir Crit Care Med. -1995. -Vol. 151.-P. 1715-1719

193. Dowling R.B, Rayner C.F., Rutman A., al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. //Am J Respir Crit Care Med 1997. Vol. 155(1).-P. 327-36.

194. Drake A.J., Howells R.J., Shield J.P.H. et al. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. //BMJ 2002. - Vol. 324.- P. 1081-1083

195. Drummond M. Economic evaluation in Health Care. Oxford University Press 2001

196. Drummond M., Abdalla N., Buckingham J.K. Integrated care for asthma: a clinical, social, and economic evaluation. //BMJ 1994,- Vol. 308.-P. 559-564

197. Edwards A., Stevens M.T. The clinical efficacy of inhaled nedocromil sodium (Tilade) in the treatment of asthma)// Eur Repir J- 1993;-Vol.6. P. 35- 41.

198. Edwars A., Holgate S., Howell J. Sodium cromoglicate in childhood asthma. //Thorax 2001; Vol. 56.- 331-332

199. Esenberg J.M., Schulman K.A, Glick H., Koffer H. Pharmacoeconomics: economic evaluation of pharmaceuticals. In Strom BL ed., Pharmacoepidemiology, 2nd ed. New York: J Wiley, 1994

200. Ernst P., Spitzer W.O., Suissa S. et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA -1992,- Vol. 268.- P. 3462-3464

201. Evans R. Safety of Nedocromil sodium, 4 inhalations, BID, in children. //Ann.Allergy. -1995. -P. 37

202. Evans P. M., O'Connor B. J., Fuller R. W. et al. Effect of inhaled corticosteroids on peripheral eosinophil counts and density profiles in asthma.//J. Allergy Clin. Immunol. -1993.-Vol. 91.-P. 643-649

203. Expansion of Quality Measures (Q-SPAN). Agency for Health Care Policy and Reaserch. Rockville, MD.01/12/88. http://www.ahrq.gov/qual/qspanovr.htm

204. Fahy J.V., Kim K.W., Liu J., Boushey H.A. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. //J Allergy Clin Immunol 1995; -Vol. 95.- P. 843-52

205. Falcoz C., Mackie A., McDowall J. et al. Oral bioavailability of fluticasone propionate in healthy subjects. //Br.J.Clin.Pharmaco. -1996; -Vol. 41. -P.459-60

206. Fanslow W.C., Andeson D.M., Grabastein K.H. et al. Soluble forms of CD40 inhibit biologic responses of human B cells. //J.Immunol. -1992. -Vol.149. -P. 655-660

207. Faurschou P. Chronic dose-ranging studies with salmeterol. //Eur.Resp.Rev. -1991.-Vol 1.-P. 282-287

208. Fink-J.N., Forman S., Silvers W.S. et al. A double-blind study of the efficacy of nedocromil sodium in the management of asthma in patients using high doses bronchodilators. //J. Allergy. Clin. Immunol.- 1994.-Vol. 94. -P. 473-481

209. Finn A.F., Thompson C.M, Banov C.B. et al. Inhaled beta-agonist induced syncope.//Ann.Allergy.- 1995.-A97

210. FitzGerald M. Acute asthma. Extract from "Clinical Evidence". //BMJ 2001.-Vol. 323.-P. 841-845

211. Foo A.L., Lanteri C.J., Burton P.R. The Effect of nedocromil sodium on Histamine Rwsponsiveness in Clinically Stable Asthmatic children// J. of Asthma.-1993.-Vol. 30(5), P. 381-390

212. Foreman J.C., Hallet M.B., Mongar J.L. Site of action of the antiallergic drugs cromoglycate and doxantrazle.// Br J.Pharmacol -1977:-Vol. 59.- 473P(abstract).

213. Foresi A., Chetta A., Pelucchi A. et al. Effects of disodium cromogligate and nedocromil sodium on propranolol-induced bronchoconstriction// Ann.Allergy.- 1993.-Vol. 70 (2).-P. 159-163

214. Fredberg J.J. Airway smooth muscle in asthma. Perturbed equilibria of myosin binding.// Am J Respir Crit Care Med 2000; - Vol. 161.- P. 158-60

215. Friday G.A., Khine H., Lin M.S. Profile of children requiring emergency treatment for asthma. //Ann.Allergy.Asthma.Immunol.-1997.-Vol. 78(2). -P. 221-224

216. Fris U., Johanses T., Hayes N., Foreman K. IgE-receptor activated cjprode Itale on relation to histamine secretion from mast cells. //Br J Pharmacol- 1994- Vol.111.- P. 1179-83.

217. Fyans P., Chatterjee P., Chatterjee S. Effects of adding nedocromil sodium (Tilade) to the routine therapy of patients with bronchial asthma. //Clin Exp Allergy -1989- Vol. 19-P. 521-8.

218. Gilman G. Comparison of aerosolized glycopyrrolate and metaproterenol in acute asthma. //Am. Rev. Biochem. 1987.- Vol. 56.- P. 615-649

219. Glaxo Canada. The cost of adult asthma in Canada. Priceton, NJ: Communications Media for Education, 1993

220. Global Strategy for Asthma Management and Prevention.NHBL/WHO Workshop Report.National Institutes of Health National Heart.Lung. and Bloodlnstitute. Publication number 95-3659. January 1995.

221. Godfrey S., Balfour-Lynn S., Konig P. The place of cromolyn sodium in the long-term management of asthma based on a 3- to 5-year follow up.// J.Peadiatr. 1975.-Vol. 87.-P. 465-73

222. Gooden D., Ross S., Abdaila M. Outcome of wheeze in childhood: symptom and pulmonary function 25 years later.// Am.J.Resp.Crit.Med. -1994- Vol.l49(l).- P. 106-112

223. Grahnen A., Eskernas S-A., Brundin RM. et al. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy Volunteers.//Br.J.Clin.Pharmacol. 1994; -Vol. 38. -P.521-525

224. Gravelyn T.R., Pan P.M., Eschenbacher W.L. Mediator release in an isolated airway segment in subjects with asthma.//Am Rev Respir Dis 1988:-Vol.l37-P. 641-6.

225. Greening A.P., Ind P.W., Northfield M. Addend salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticostyeroids // Lancet.- 1994,- Vol. 344.- P. 219-224

226. Greif J., Fink G., Smorzik Y et al. Nedocromil sodium and placebo in the treatment of bronchial asthma. //Chest. 1989. -Vol.96,- P. 583-588.

227. Gribben M.P., MacDonald N., McFadden E.R. Short- and long-term effects of cromolyn sodium on the airway reactivity of asthmatics. //J.Allergy.Clin.Immunol.-1983;- Vol. 7(3).- P. 331-8

228. Griffits C., Sturdy P., Naish J. Hospital admission for asthma in east London: association with characteristics of local general practices, prescribing and population.// BMJ 1997; - Vol. 314.- P. 482-492

229. Grimes D.A. Technology follies: the uncritical acceptance of medical innovation. //JAMA 1993; Vol. 269(23).- P. 3030-3

230. Guite H.F., Dundas R., Burney P.G. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. // Thorax 1999; - Vol. 54.- P. 301-307

231. Guyatt G.II. Children and adults perceptions of childhood asthma.// Pediatrics 1997.- Vol. 99.-P. 166-8

232. Haahtela T., Jarvinen M., Kava T. et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N. Engl. J. Med.- 1994. Vol. 331.-P. 700-705

233. Haahtela T. The disease management approach to controlling asthma.// Resp Med 2002. - Vol. 96 (Suppl A).- SI-8

234. Hakim E.A, Hide D., Kuzemko J. Can nedocromil sodium substitute for sodium cromoglycate in children with asthma.// Eur.Resp. J.- 1994,- Vol.7 (Suppl. 18).- 139S

235. Hardeen A.R, Woods S., Heider S. Efficacy of nedocromil sodium used with spacer device in the younger asthmatic.// Eur.Resp. J. -1994.-Vol. 7 (Suppl. 18). -139S

236. Harding S.M. The human pharmacology of fluticasone proionate.//Resp. Mad. -1990; -Vol.84 (Suppl. A).-P. 25-29

237. Heaney L.G., Shields M.D., Cadden I.S. et al. Non-bronchoscopic lavage of paediatric airways: evidence for ongoing airway inflammation in childhood asthma. //Clin Exp. Allergy -1994:- Vol.24.- P. 991 (abstract).

238. Hindmarsh P. Exogenous glucocorticoids influence adrenal function, but assessment can be difficult. //BMJ. 2002; - Vol. 324.-P. 1083

239. Ho A. S., Moore K. W. Interleukin-10 and its receptor.// Ther. Immunol. 1994. -Vol. 1.- P.173-185

240. Hogger P., Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. // Steroids. 1994.- Vol. 59,- P. 597-602

241. Holgate S.T., Davies D.E., Lackie P.M. et al. Epithelial-mesenchymal interactions in the pathogenesis of asthma.// J Allergy Clin Immunol 2000; - Vol. 105.- P. 193-204

242. Holt S., Suder A., Weatherall M., et al. Dose-response relation of fluticasone propionate in adolescents and adults with asthma: meta-analysis. //BMJ 2001 - Vol. 323,- P. 253-6.

243. Howart P.H. Rhinits and Asthma: Links and Optimal Treatment// Clin. Exper. Allergy. -1998. -Vol.28. (Suppl.2).- P. 1

244. Howarth P.H. What is the nature asthma and where are the therapeutic targets? //Resp.Med. -1997-Vol. 91 (Suppl.A).- P. 2-8

245. Holt S., Suder A., Weatherall M., et al. Dose-response relation of fluticasone propionate in adolescents and adults with asthma: meta-analysis. //BMJ 2001 - Vol. 323.- P.253-6.

246. Integrated care for asthma: a clinical, social, and economic evaluation. Grampian Asthma Study of Integrated Care (GRASSIC)//BMJ. 1994 - Vol. 26 - N. 308(6928) -P. 559-64.

247. Jabara H.H., Fu S.M., Geha S. et al. CD40 and IgE synergism between anti-CD40 mAB and IL-4 in the induction IgE synthesis by highly purified human B cells. // J.Exp. Med. 1990. -Vol.172. -P. 1861-1864

248. Jackson D.M., Norris A.A., Eady R.P. Nedocromil sodium and sensory nerves in the dog lung. //Pulm Pharmacol -1989:- Vol.2. P. 179-84.

249. Jacson D.M., Eady R.P., Farmer J.B. The effect of nedocromil sodium on nonspecific bronchial hyperreaktivity//Eur. J. Resp.Dis. -1986.-Vol. 69 (Suppl.147). -P. 217-219

250. Jackson R.T. Mechanism of action of some commonly used nasal drugs. //Otholaringol Head Neck Surg -1992; -Vol. 107.- P. 433-40

251. Jaffuel D., Demoly P., Gougat C., Balaguer P., et al. Transcriptional potencies of inhaled glucocorticoids. //Am J Respir Crit Care Med 2000 - Vol. 162(1).- P.57-63.

252. Jenkings M., Hoppes J., Bowes G. et al. Factors in childhood as predictors of asthma in adult life.// Br. Med. J.- 1994. -Vol. 309 (6947).- P. 90-93

253. Jenner W.N., Kirkham D.J. Immunoassay of beclomethasone 17, 21-dipropionate and metabolites. In: Reid E, Robinson JD, Wilson I, eds. Bioanalysis of drugs and metabolites. Pneum, New York; 1988. P. 77-86

254. Johansson S-A., Meisen W.M.A.J., Pelikan D.M.V. Delayed Asthmatic response and the protective effects of disodium cromogligate and nedocromil sodium and beclomethasone diproionate///Allergy.Clin.Immunol.- 1996.-Vol.97 (1,3).-P. 253

255. John M., Lim S., Seybold J. et al. Inhaled corticosteroids increase IL-10 but reduce MIP-1, GM-CSF and IFN-release from alveolar macrophages in asthma (abstract). //Am. J. Respir. Crit. Care Med. 1997. - Vol. 155.- A287 .

256. Johnson M., Coleman R.A. Mechanisms of action of ß2-adrenoreceptor agonists. In: Asthma and Rhihitis (Ed. W. Busse, ST Holgate). Blackwell 1995,- P. 1278-1295

257. Johnson M. Salmeterol./ZMedicinal Research Reviews. 1995.- Vol. 15.- P. 225257

258. Johnson M., Butchers P.R., Coleman R.A. et al. The pharmacology of salmeterol//. Life Sciences 1993.-Vol.52(26).-P. 2131-2147

259. Johnson M. The beta-adrenoceptor.// Am J Respir Grit Care Med 1998. - Vol. 158(5 Pt3).-S 146-53.

260. Jones: P.'W. Quality of life, symptoms and; pulmonary function in asthma: long-term treatment* with examined in a controlled multicentre! trial .//Eur.Res.J. -1994. -Vol.7(l);-P. 55-62

261. Katz Y., Lebas F.X., Medley H.V. et al. Fluticasone propionate 50 mg BID versus 10 mg BID in the treatment ofchildrcn with persistent asthma. //Clin Ther 1998; - Vol. 20.- P. 424-37 ' .

262. Keech Mi Using health; outcomes data to inform decision-making. A pharmaceutical industry perspective. //Pharamacoeconomics 2001 - Suppl. 2,- P. 27-31

263. Kielhorn A., Molima J., Nabersn K Outcomes research study assessing resource utilization for the treatment; of asthma exacerbation in primary care in Spain. //Val Health -2000.-Vol. 3.-P. 332

264. Kimata H., Mikawa H. Nedocromil sodium selectively inhibits IgE and IgG4 production in human B cells stimulated with IL4. //J.Immunol. -1993. -Vol.51.-P. 672332

265. Kips K.C., O'Connor B.J., Inman K. ct al. A long-term study of the antiinflammatory effect; of low-dose budesonode plus formoterol versus high-dose budesonide in asthma. //Am J Respir Crit Care Med 2000, Vol. 161.- P. 996-1001

266. Kirby S., Falcoz C., Daniel M.J., Milleri S., et al. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. //Eur J Clin Pharmacol 2001. -56(11).- P.781-91.

267. Kita H., Abu-Ghazaleh R., Sanderson C. J., Gleich G. J. Effect of steroids on immunoglobulin-induced eosinophil degranulation.//J. Allergy Clin. Immunol. 1991. -Vol. 87.- P. 70-77

268. Konig P., Eigen H., Ellis H. et al. The effect of nedocromil sodium on childhood asthma during the viral season// Am.J. of Resp.Crtit.Care Med.- 1995. -Vol.152 (6 Ptl). -P.1879-86

269. König P., Ford L., Galant S. et al. A 1 year comparison of the effects of inhaled fluticasone propionate (FP) and placebo on growth in prepubescent children with asthma.//Eur.Resp.J. -1996; -Vol.9. -P. 294

270. König P., Hordvik N.L., Kretz B.S. The preventive effect and duration of action of nedocromil sodium and sodium cromogligate on exercise-induced asthma (EIA) in adults// J. Allergy.Clin. Immunol. -1987. -Vol.79 (1), -P. 64-68

271. König P., Johnson J.S, Treatment of childhood asthma with anti-inflammatory drugs, according to guidelines, is cost-effective. //Eur Resp 1998; - Vol. 12 (Suppl 28).-P. 88

272. Korn S.H., Wouters E.F., Wesseling G., Arends J.W., et al. In vitro and in vivo modulation of alpha- and beta-glucocorticoid- receptor mRNA in human bronchial epithelium. //Am J Respir Crit Care Med -1997 Vol.155 (3).- P. 1117-22.

273. Korsch B.M., Negrete V.F. Doctor-patient communication. //Sei Am 1972 Vol. 227 (2).- P. 66-74

274. Krahn M., Berka C., Langlois P. et al. Direct and indirect costs of asthma in Canada 1990. //Canadian Medical Association Journal 1996. - Vol. 154.- P. 821-831

275. Krroegel C., Virchow JC, Walker C. Asthma //N. Engl J Med. 1993- Vol.328.- P. 1639-4.

276. Lagerlov P., Leseth A., Matheson I. The doctor-patient relationship and the management of asthma.// Soc Sci Med 1998 - Vol. 47.- P. 85-91

277. Lahdensuo A., Haahtela T., Herrala J.P. et al. Randomized comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. //BMJ 1998.-Vol. 316.-P. 1138-1139

278. Laitinen L.A., Laitinen A. Innervation. Airway Smooth Muscle Workshop. //Am.Rev. Resp.Dis. -1987 Vol. 26. - P. 245-247

279. Laitinen L.A., Laitinen A., Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonid, and of a B2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma.//J.Allergy Clin Immunol -1992 -Vol.90. -P. 32-42

280. Laitinen L. A., Laitinen A., Heino M., Haahtela T. Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid.// Am. Rev. Respir. Dis. -1991.- Vol. 143.- P. 423-427

281. Lam S., Chan H., LeRichie JC. et all. Release of leukotrienes in patients with bronchial asthma.//J.Allergy Clin Immunol -1998- Vol.81.- P. 711-7

282. Lancry P-J., O'Connor R., Stempel D., Raz M. Using Health Outcomes Data to Inform Decision-Making. Healthcare Payer Perspective. //Pharmacoeconomics 2001. -Vol. 19(Suppl2).-P. 39-47

283. Langdon C.G., Capsey L.J. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma.// Br. J. Clin. Res. 1994.- Vol. 5 - P. 85-99

284. Leff A. R. Dose response relationships in determining the safety: efficacy ratio. //Resp Med 1997.- Vol. 91(Suppl. A).- P. 34-37

285. Leff A.R. Inflammatory mediation of airway hyperresponsveness by peripheral blood granulocytes. The case for the eosinophil. //Chest 1994. - Vol. 106. -P. 1202-8

286. Lewis M.A., Kuhl-Habich D., Von Rosen J. Drug use adverse event monitoring in German children// Int J Clin Pharmacol Ther -2001.-39 (Suppl 11).- P. 507-12

287. Ley P. Communicating with patients: improving communication, satisfaction, and compliance. New York: Croom Helm, 1988

288. Liu M.C., Blecker E.R., Lichtenstein L.M. et al. Evidence for elevated levels of histamine. Prostaglandin D 2and other bronchoconstriciting prostaglandins in the airways of subjects with mild asthma. //Am Rev Respir Dis -1990- Vol.142.-P. 126-32.

289. Lloyd A.R, Openheim J.J. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. //Immunol Today 1992. - Vol. 13,- P. 169-72

290. Loch R.K.S, Jabara H.H, Geha H. et al. Mechanisms of inhibition of IgE synthesis by nedocromil sodium: nedocromil sodium inhibits dcletional switch recombination human B cells. //J. Allergy Clin. Immunol. -1996.-Vol.97. -P. 1141-50

291. Lowhagen 0., Rak S. Modification of bronchialhyperreactivity after treatment with sodium cromoglycate during pollen season.// J. Allergy. Clin.Immunol. 1985- Vol. 75(4).- P. 460-467

292. Lundback B., Price M.J., Thwaites R.N.A et al. The cost-effectiveness of salmeterol/fluticasone propionate combination product and budesonide in asthma.// Eur. Respir J 1999. - Vol. 14 (Suppl 30).- P. 370s

293. Lundback B. Epidemiology of rhinitis and asthma// Clin.Exp.Allergy.-1998, -Vol.28(Suppl.2).- P. 3-7

294. Mackie A., Vantresca G., Fuller R, Bye A. Pharmacokietics of intravenous fluticasone propionate in healthy subjects. //Br.J.Clin.Pharmacol.- 1996- Vol. 41. P. 539-542

295. Malech H.L., Gallin J.I. Current concepts: immunology. Neutrophils in human diseases.// N Engl J Med 1987. - Vol. 317.- P. 687-94

296. Manolitsas N.D., Wang J.H., Devalia J.L. et al. Regular albuterol, Nedocromil sodium and bronchial inflammation in asthma. //Am J Respir Crit Care Med 1995- Vol. 151

297. Martin A.J., Landau L.I., Phelan P.D. Asthma from chilhood at age 21: the patient and his or her disease// Br.Med.J. -1982. -Vol. 284. -P. 380-382

298. Martin R., Cicutto L., Smith H. et al. Airways inflammation in nocturnal asthma. //Am Rev Respir Dis-1991-Vol. 143-P. 351-7.

299. Mash B., Bheekie A., Jones P.W. Inhaled vs oral steroids for adults with chronic asthma. //Cochrane Database Syst Rev 2000.- Vol. 2

300. McFadden E.R. Hypothesis Exercise-induced asthma as a vascular phenomena. //Lancet. -I990.-Vol. 335,-P. 880-883

301. McAlpine L.G., Thomas N.C. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta2-adrenergic agonist.// Respir Med. -1990. Vol. 84.-P.293.

302. McMahon A.D., McDonald T.M. Design issues for drug epidemiology// Br J Clin Pharmacol. 2000 - Vol. 50. - P. 419-425

303. Minette P.A.H., Lammers J., Dixon C.M.S. et al. A muscarinic agonist inhibits reflex bronchoconstriction in normal but not in asthmatic subject. //J Appl Physiol- 1989-Vol. 67.-P. 2461-5.

304. Mollmann H., Meibohm B., Hochhaus G. et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration.// Eur.J.Clin.Pharmacol. 1998 - Vol. 143- P. 351-7.

305. Moor B.B., Weiss K.B. A community-based study of asthma deaths and near deaths //J Allergy Clin Immunol. 1995. - Vol. 95 (lPt2).- P. 274

306. Moore R., Mao Y., Zhang J. et al. Economic burden of illness in Canada, 1993. Laboratory Centre for Disease Control, health Protection Branch, health Canada, Ottawa. Cat No H21-136/1993E, 1997

307. Morton A.R., Ogle S.L., Fitcn K.D. Effects of Nedocromil sodium and cromoline sodium and placebo on exercise-induced asthma// Ann.Allergy.- 1992.-Vol. 68 (2), -P. 143-148

308. Munch E.P., Taudorf E., Weeke B. Dose frequency in the treatment of asthmatics with inhaled topical steroid.// Eur.J.Respir.Dis. 1982 -Vol. 63 (Suppl.122,143-152)

309. Murphy S., Kelly H.W. Cromolyn sodium: a review of mechanisms and clinical use in asthma. //Drug. Intell.Clin.Pharm.- 1987-Vol. 21(1). P. 22-35

310. Myeers A.C., Undem B.J., Fischer A., Kummer W. Comparison of tracheal and bronchial sensory enervation of guinea pig airway parasympathetic ganglion neurons.// Am Rev Respir Crit Care Med -1995- Vol. 151(4).- A816 (abstract).

311. Myers A.C., Undem B.J. Electophysiological effects of tachykinins and capsacin on guinea-pig bronchial parasympathetic ganglion neurones.// J Physiol 1993- Vol. 470-P. 665-79

312. Myers A.C., Undem B.J., Fischer A., Kummer W. Comparison of tracheal and bronchial sensory enervation of guinea pig airway parasympathetic ganglion neurons.// Am Rev Respir Crit Care Med -1995- Vol. 151(4)- A816 (abstract).

313. Mygind N. Hypersecretion in the airways. In: Andrews P, Widdcombe J, eds Patophysiology of Gut and Airways. London: Portland Press, 1993.- P. 47-57

314. Nadel J.A., Takeyama K., Agusti C. Role of neutrophil elastase in hypersecretion in asthma.//Eur. Respir J 1999; - Vol. 13.- P. 190-6

315. Nadel J.A. Neutral endopeptidase modulates neurogenic inflammation.// Eur Respir J -1991- Vol.4.- P.75-54.

316. Nathan C.F. Secretory products of macophages. //J Clin Invest 1987. - Vol. 79.-P. 319-26

317. National Asthma Campaign. Report on the cost of asthma in Australia. National Asthma Campaign, 1992

318. National Asthma Education and Prevention Program Quick Reference: NAEPP Expert Panel Guidelines for the Diagnosis and Management of Asthma-Update on Selected Topics 2002. NIH Publication No 02-5075

319. National Asthma Education and Prevention Programme Expert Panel report II. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institute of Health, 1997 (Publication 97 4051).

320. National Asthma Education and Prevention Task Force on the Cost Effectiveness, Quality of Care, and Financing of Asthma care. NIH Publication. No. 55-807. National Institute of Health. 1999

321. National Heart, Lung and Blood Institute. Chapter 8. Socioeconomics. In: Global strategy for asthma management and prevention NHLBI/WIIO workshop report. Bethesda, MD: US Department of Health and Human Services, 1994. NIH publication no. 94-3276

322. National Heart, Lung, and Blood Institute. Expert panel report: guidelines for the diagnosis and management of asthma. Bethesda, MD: US Department of Health and Human Services, 1991. NIH publication no. 91-3042.

323. Nelson H.S. Beta-adrenergetic bronchodilatators.// N Engl J Med 1995. - Vol. 333.-P. 499-506

324. Nelson H.S., Busse W.W., Kerwin E. et al Fluticasone propionate/ salmeterol combination provides more effective asthma control than low dose inhaled corticosteroid plus montelukast // J Allergy Clin Immunol 2000. - Vol. 106.- P. 1088-1095

325. Neville R.G., Pearson M.G., Richards N. et al. A cost analysis on the pattern of asthma prescribing in the UK. //Eur Resp J. 1999. - Vol. 14.-P. 605-609

326. Newhman D.M. Metered-dose inhalers: mouth open or closed? // JAMA. 1994 -Vol. 26.- P. 272-3

327. Newnman D.M., McDevitt D.G., Lipworth B.J. Bronchodilator subsensitivity after chronic dosing with formoterol in patients with asthma. //Am J Med 1994. -Vol. 97(1).-P.29-37.

328. Newman S.P., Pavia D., Clarke S.W. Improving the bronchial deposition of pressurised aerosols.//Chest.-1981- Vol. 80 .-P. 909-911

329. Newman S.P. Aerosol deposition considerations in inhalation therapy. //Chest 1985. Vol. 88 (Suppl).- P. 152-60S

330. Newman S.P., Clarke S.W. Therapeutic aerosols. 1. Physical and practical consideration, (editional).//Thorax. -1983, -Vol.38. -P. 881-886

331. Noble V., Ruggins N., Everard M., Milner A. Inhaled budesonide for chronic wheezing under 18 months of age.// Arch Dis Child 1992. - 67. -P. 285-288

332. Nocker R.E., Weller F.R., Out T.A., et al. A double-blind study on the effect of inhaled corticosteroids on plasma protein exudation in asthma. //Am J Respir Crit Care Med 1999. - Vol. 159.- P.1499-1505

333. Norris A.A. The effects of nedocromil sodium and sodium cromogligate on Airway Nerves and Neurogenic Responses in Asthma./ZPulmon. Pharmacology. 1995.-Vol. 8.- P. 227-230

334. Northrop J. P., Ullman K. S., Crabtree G. R. Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT). //J.Biol. Chem. 1993. - Vol. 268,- P. 2917-2923

335. O'Callaghan C., Barry P. Delivering inhaled corticosteroids to patients. //BMJ -1999.-Vol. 318.- P.410-411

336. O'Connor R.D., Wangs S.W., Pinto L.A. et al. Two-year retrospective economic evaluation of three dual-controlled therapies used in the treatment of asthma. //Ann Allergy Asthma Immunol 2001. - Vol. 86.- P. 81

337. O'Connor B. J., Aikman S. L., Barnes P. J. Tolerance to the non-bronchodilator effects of inhaled beta agonists in asthma.// N. Engl. J. Med.- 1992. Vol. 327.- P. 12041208

338. Oddera S., Silvestri M., Testi R., Rossi G.A. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. //Respiration 1998. -Vol. 65(3).- P.199-204.

339. O'Hickey S.P., Arm J.P., Rees P.J. et al. The relative responsiveness to inhaled leukotriene E4. Methacholine and histamine in normal and asthmatic subjects.// Eur Respir J -1988:- Vol.1.-P. 913-7.

340. Okayama Y., Petit-Frere C., Kasssel O. et all. Expression of Mrna for IL-5 and IL-4 in human mast cells in response to Fc-receptor cross-linking and the presence of stem cell factor //J. Immunol.- 1995.- 155(4)- P. 1796-808.

341. Palmqvist M., Persson G., Lazer L., et al. Inhaled dry powder formoterol and salmeterol in asthmatic patients onset of action, duration of effect and potency. //Eur Resp J 1997. - Vol. 10.- P. 2484-2489

342. Pang L., Knox A. J. Synergistic Inhibition by beta 2-Agonists and Corticosteroids on Tumor Necrosis Factor-alpha -Induced Interleukin-8 Release from Cultured Human Airway Smooth-Muscle Cells. //Am J Respir Cell Mol Biol -2000,- Vol. 23,- P. 79-85

343. Parcel G.S., Gilman S.C., Naden P.R., Bunce H. A comparison of absentee rates of elementary schoolchildren with asthma and nonasthmatic schoolmates. //Paediatrics. -1979.-Vol. 64(6).-P. 878-81

344. Park C.S., Lee S.M., Uh S.T. et all. Soluble interleukin -2 receptor and cellular profiles in bronchoalveolar lavage fluid from patients with bronchial asthma.// J.Allergy Clin Immunol- 1993- Vol. 91.- P. 623-33.

345. Patel L., Wales J.K, Kibrige M.S. et al. Symptomatic adrenal insufficiency during inhaled steroid treatment. //Arch Dis Child 2001. - Vol. 85.- P. 330-334

346. Paulmichl M., Li Y., Wichmann K. et all. New mammalian chloride channel identified by expression cloning.//Nature- 1992- Vol.356- P. 238-41.

347. Pauwels R. A., Lofdahl C.-G., Postma D. S. et al. The effect of inhaled formoterol and budesonide on exacerbations of asthma. //N. Engl. J. Med. 1997. - Vol. 337.- P. 1405-1411

348. Pearlman D.,Chervinsky P., LaForce C. et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.// N.Engl. J. Med. 1992.-Vol. 327.-P. 1402-140

349. Pearlman D.S., Noonan M.J., Tashkin D.J., et al. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. //Ann Allergy Clin Immunol 1997- Vol. 78,- P. 356-62.

350. Pedersen S., Hansen O.R., Fuglsang G. Influence of respiratory flow rate upon the effect of a turbohaler.//Arch. Dis. Child.-1990- Vol.65.- P. 308-319

351. Pedresen S. Clinical issues in paediatric asthma. //Resp.Med.J. -1997; -Vol.91 (Suppl.A).- P. 40-41

352. Phillips G.D., Holgate S.T. The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5 -monophosphate in non-atopic asthma.// Am Rev Respir Dis 1989:- Vol.139.- P. 463-9.

353. Phillips G.D., Scott V.L., Richards R., Holgate S.T. Effect of nedocromil sodium and sodium cromogligate against bronchoconstriction induced by inhaled adenosine 5-monophosphate//Eur.Resp.J. 1989, -Vol.2. -P. 21-217

354. Pieters W.R., Wilson K.K, Smoth H.C.E., Tammimga J.J. Cost-effectiveness of fluticasone propionate/salmeterol combination product and fluticasone propionate/montelucast in asthma.// Am J Respir Crit care 2001. - Vol. 163(5).- A463

355. Pilnick A., Dingwall R., Starkey K. Disease management: definitions, difficulties and future decision. //Bulletein of the WHO -, 2001.- Vol. 79 (8)

356. Powell C.V.E., Everard M.L. Treatment of childhood asthma. Options and rationale for inhaled therapy. //Drugs. 1998. Vol. 55,- P. 237-252

357. Premaratne U.N., Sterne J.A.C., Marks G.B. et al. Clustered randomized trial of an intervention to improve the management of asthma: Greenwich asthma study. //BMJ -1999-Vol.318.- P. 1251-1255

358. Price H.V. Cromolyn sodium: • post-market surveillance.// ImmunoLAllergy.Practice. 1986 -Vol. 8.-P. 3340

359. Price J.F. Corticosteriods and other anti-inlammatory agents in the treatment of children. // Eur. Respir.Rev. -1994.-Vol. 4(17). -P. 27-32

360. Price J.F., Weller P.H. Comparison of fluticasone propionate and sodium cromogligate for the treatment of childhood asthma// Resp.Med.- 1995.-Vol. 89 (5). -P. 363-8

361. Price M.J., Brigs A.H. Development of an Economic Model to Assess the Cost Effectiveness of Asthma management strategies. //Pharmacoeconomics 2002 - Vol. 20 (3).-P. 183-194

362. Rabe K.R., Munoz N.M., Vita A.J. et al. Contraction of human bronchial smooth muscle caused by activated human eosiophils. //Am Rev Respir Dis 1993.- Vol. 147.-P.677-83

363. Raisch D.W. Understanding quality-adjusted life and their application to pharmacoeconomic research //Ann Pharmacother 2000.- Vol. 34(7-8).- P. 906-14

364. Rao R., Gregson R.K, Jones A.C., et al. Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: a comparison of fluticasone with beclomethasone//. Eur Respir J. 1999.- Vol. 12,- P. 87-94.

365. Rees T.P., Lennox B., Timney A.P. et al Comparison of increasing the dose of budesonide to 800 ng/day with maintained dose of 400 jig/day in mild-to-moderate asthmatic patients.// Eur J Clin Res 1993. - Vol. 4.- P. 27-34

366. Rhodes D.G., Newton R., Butler R., Herbette L. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers. //Molecular Pharmacology. -1992.- Vol. 42.- P. 595-602

367. Richards R., Philips G.D., Holgate S.T. Nedocromil sodium is more potent than sodium cromoglycate against AMP induced bronchoconstriction in atopic asthma subjects. //Clin Exp Allergy 1989- Vol. 19.- P. 285-91

368. Roghman M.C., Sexton M. Adherence to asthma guidelines in general practices. //J Asthma 1999. - Vol. 36.- P. 381-387

369. Romanin C., Reinspreecht M., Pecht I., Schindler H. Immunologically activated chloride channels involved in degranulation of rat mucosal mast cells. //EMBO J -1991-Vol.10.-P. 3606-8.

370. Ruten-van Mölken M.P.M.H., Van Doorslaer E.K.A., Jansen M.C.C. et al. Cost and effects of inhaled corticosteroids and bronchodilatators in asthma and chronic obstructive pulmonary disease.//Am J Crit care Med 1995. - Vol. 151 (4).- P. 975-82

371. Rutstein D.D., Berenhberg W., Chalmers W. et al. Measuring the quality of medical care: a clinical method.// N Engl J Med 1976. - Vol. 294 (11).-P. 582-8

372. Ruud A., Hein J.J., Maikoe T. et all. Inhibition of cytocine-primed eosinophil Chemotaxis by nedocromil sodium//J.Allergy.Clin.Immunol. -1993. Vol. 91. -P. 802809

373. Sackett D.L., Haynes R.B. Compliance with Therapeutic Regiments. Baltimore. 1976

374. Sammers Q. A., Honywell R., Renwik A.G. et al. The protective efficacy of inhaled, oral and intravenous Nedocromil sodium against adenosin-5-monofosfat induced bronchoconstriction in asthmatic Volunteers. //Pulm. Pharmacol. -1990,-Vol. 3. -P. 190197

375. Satiader L., Doroic D.D., Venho K.K. et al. Nedocromil sodium is more effective than Cromolin sodium for the treatment of chronic reversible obstructive airway disease// Chest. 1993.-Vol. 104 (2). -P. 438-447

376. Schwiebert L. A., Beck L. A., Stellato C. Et al. Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions.//J. Allergy Clin. Immunol. 1996. -Vol. 97.-P. 143-152422. Scrip.- 1992. no 1755

377. Serra-Batlles J., Plaza V., Morejon E. at al. Cost of asthma according to the degree severity. //Eur Resp J 1998. - Vol. 12. - P. 1322-1326

378. Settipane G.A, Klein D.E., Boyd G.K. et al. Adverse reactions to cromolyn.// JAMA- 1986-Vol. 241.- P. 811-13

379. Shields M., McCollum J., Irvine M. One year of treatment with flavoured nedocromil sodium in young children// Eur. resp. J'. -1994. -Suppl.18.- A 0702, (s.139)

380. Shrewsbury S., Pyke S., Britton M. Meta -analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma. IIBr. Med. J. 2000 - Vol. 320. - B68-1373

381. Sim D., Griffiths A., Armstrong D. et al. Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma //Europ Resp J 2003 . - Vol 21(4).-P. 633-636(4)

382. Skoner P.P. Szefler S.J. Welch M. et al. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma.// J Allergy Clin Immunol. 2000 - 105(2 Pt 1) - p. 259-68.

383. Simins F. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate Salmeterol Xinofoate Study Group. IIN Eng J Med 1997. -Vol. 4.- P. 1659-1665

384. Sittard R.J. Health Outcomes Data to decision-making. Formular Committee perspective. //Pharmacoeconomics 2001. - Vol. 19(Suppl 2).- P. 49-52

385. Smith C.M., Hawksworth R.J., Thien F. et al. Urinary leukotriene E4 in bronclxial asthma. //Eur Respir J 1992.-Vol.5. -P. 693-9.

386. Smith M.N.J., Hodson M.E. Effects of long term inhaled high close beclomethasone dipropionate on adrenal function.// Thorax.-1983- Vol. 38.- P. 76-81

387. Sonrergaard B., Davidsen F., Kikerby B. et al. The economics of an education program for adults who have asthma.// J Gen Intern Med 1991. - Vol. 6.- P. 401-7

388. Sorva R., Turpeinen M., Juntunen K. Et al. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. //J. Allergy Clin. Immunol. 1992. -Vol. 90,- P. 808-815

389. Sotomayor H., Badier M., VerVoloet D., Orchek J. Seasonal increase of carbochol airway responsiveness in patients allergic to grass pollen. Reversal by corticosteroids. //Am.Rev.Respir.Dis. -1984- Vol. 130. P. 56-8

390. Spahn J.D., Leung D.Y.M. The role of glucocorticoids in the management of asthma.//Allergy AsthmaProc -1996. -Vol. 17- P. 341-50

391. Spector S.L. Update on exercise-induced asthma// Ann.Allergy. -1993. -Vol.71 (6).- P. 571-577

392. Speight A.N., Lee D.A., Hey E.N. Under diagnosis and under treatment of asthma in childhood. //Br Med J (Clin Res Ed) 1983 - Vol. 286 (6373).- P. 339-43

393. Spizer W.O., Suissa S.A., Ernst P. et al. The use of p-agonists and the risk of death and near death from asthma. //N.Ingl.J.Med. 1992.- Vol. 326.- P. 501-506

394. Springer T.S. Adhesion receptors of the immune system.// Nature 1990-Vol.346.- P. 425-34.

395. Stafford W.P., Yarbrough J., Mansfield L.E. Cromolyn modifies histamine reactivity in symptomatic seasonal asthma. //Ann.Allergy. -1984. -Vol.52.- P. 401-5

396. Steffensen I., Faurschou P., Riska H. Inhaled formoterol drypowder in the treatment of patients with reversible obstructive airway disease. //Allergy, 1995.- Vol. 50.- P. 657-663

397. Stewart-Bron S., Haslum M. Partial sight and blindness in children of the 1970 birth cohort at 10 years of age. //J Epedimiol Community Health 1988. - Vol. 42.- P. 17-23

398. Styte M., Reeves B., Wortham C. Ocular and vision defects in pre-school children. //Br J Ophtalmol 1993. - Vol. 77.- P. 228-232

399. Strom B.L. Pharmacoepidemiology. 2ed New York: John Wiley and Sons Inc 1994.

400. Suissa S., Ernst P., Benayoun S., et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. //N Engl J Med 2000. -Vol. 343.- P. 332-336

401. Suissa S.A., Ernst P., Boivin J-F. et al. A cohort analysis of excess mortality in asthma and the use of inhaled p-agonists.// Am.J.Respir.Crit.Care.Med. -1994. -Vol.149. -P.604-610

402. Suissa S.A., Ernst P., Montreal P.Q. The case-time-control design: an approach to assess the risks of adverse asthma events associated with the use of beta-aginists.// Am.J.Respir.Crit.Care.Med.- 1997; -Vol.l53(Suppl.).- A 285

403. Sullivan S., Elixhauser A., Buist A.S. et al. National Astham Education and Prevention Program Working Group report on the cost effectiveness of asthma care. //Am J Respir Crit care Med.- 1996. Vol. 154,- S84-95

404. Sullivan S. Economics of asthma and asthma treatments. //Eur Resp Rev 1998. -Vol. 8,-P. 351-355

405. Szefler S.J., Nelson U.S. Alternative agents for anti-inflammatory treatment of asthma. //J Allergy Clin Immunol 1998. - Vol. 102.- S23-25

406. Tal A. Symbicort: controlling asthma in children //Resp Med 2002. - Vol. 96(Suppl A).- S23-28

407. Tan K. S., Grove A., McLean A., et al. Systemic corticosteroid rapidly reverses bronchodilator subselectivity induced by formoterol in asthmatic patients. //Am. J. Respir. Crit. Care Med. 1997. - Vol. 156.- P. 28-35

408. Tasche M.J., Uijen J.H., Bernsen R.M. et al. Inhaled disodium cromoglycate as maintenance therapy in children with asthma: a systematic review. //Thorax 2000. Vol. 55.-P. 913-20

409. Tatar M., Santi Ambrogio G., Sant Ambrogio FB. Laryngeal and tracheobronchial cough in anaesthezied dogs.//J Appl physiol. 1994:-Vol.76.- P. 2672-9.

410. Taylor A.V., Laoprasert N., Zimmerman D., Sachs M.I. Adrenal suppression secondary to inhaled fluticasone propionate. // Ann Allergy Asthma Immunol 1999. -Vol. 83(1).-P. 68-70

411. Taylor D. R., Sears M. R., Herbison G. P. et al. Regular inhaled p2-agonist in asthma: effects on exacerbation and lung function. //Thorax. 1993. - Vol. 48.- P. 134138

412. Thomas P. Nedocromil sodium reduced emergency room visis and hospital stays.// Ann.Allergy.- 1993.-A 15

413. Thyphronitis G., Tsocos G.C., June C.H. et al. IgE secretion be Epstien-Barr virus-effected purified human B lymphocytes in stimulated by interleukin 4 and suppressed by interferon y. //Proc. Nat. Acad. Sci USA. 1989.-Vol. 86. -P. 5580-4

414. Tinkelman D., Reed C., Nelson H. et al. Aerosol beclomethasone dipropionate compared to teophylline as primary treatment of chronic mild to moderate severe asthma in children.// Pediatrics 1993. - Vol. 92.- P. 64-77

415. Todd G.R.G., Acerini C.L., Buck J.J. et al. Acute adrenal crisis in asthmatic treated with high-dose fluticasone propionate. //Eur Resp J 2002. - Vol. 19.- P. 12071209

416. Toon P.D. Reforming the Russian health service. //BMJ.- 1998 Vol. 317(7160).-P. 741-2

417. Tota M.R., Candelore M.R., Dixon R.A., Strader C.D. Biophysical and genetic analysis of the ligand-binding site of the beta-adrenoceptor. Trends Pharmacological Science-1991-12-P. 4-6

418. Turktas I., Ozkaya O., Bostanci I., Bideci A., Cinaz P. Safety of inhaled corticosteroid therapy in young children with asthma. //Ann Allergy Asthma Immunol. 2001,-Vol. 86.- P. 649-654

419. Twigg J.L. Obligatory medical insurance in Russia: the participants' perspective.// Social Science & Medicine. 1999 - Vol. 49(3).- P. 371-82

420. Ulrik C.S. Outcome of asthma: longitudinal changes in lung function. //Eur Resp J -1999. Vol. 13.-P. 904-18

421. Undem B.J., Myers A.C., Weinreich D. Antigen-induced modulation of autonomic and sensory neurons in vitro. //Int Arch Allergy Appl Imunol 1991.-Vol. 94.-P. 319-24.

422. Ungar W.J., Coyte P.C. Prospective study of the patient-level cost of asthma care in children. //Pediatr Pulmonol. 2001 - Vol. 32(2). - P. 101-8.

423. Ungar W.J., Coyte P.C., Chapman K.R. et al. The Pharmacy Medication Monitoring Program Advisory Broad. The patient level cost of asthma in adults in south central Ontario. //Canadian respiratory Journal 1998. - Vol. 5 - P. 463-471

424. Van der Molen T., Sears M., de Graaff et al. Quality of life during formoterol treatment: comparison between asthma specific and generic questionnaires. Canadian and the Duth Formoterol Investigators. //Eur. Respir. J. 1998. - Vol. 12(1).- P. 30-34

425. Van Noord J., Smeets J., Raatjmakers J. Salmeterol versus formoterol in patients with moderate severe asthma: onset and duration of action. //Eur Resp. J. 1996 - Vol. 9.-55S

426. Van Noord J., Schreurs A.J.M., Mol S.J.M. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma//. Thorax 1999.-Vol.54,- P. 207-12

427. Van Rensen E.L., Straathof K.C., Veselic-Charvat M.A., et al. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. //Thorax 1999. - Vol. 54.- P. 403-408

428. Van-Molken M.P.M.H.R., Feenstra T.L. The Burden of Asthma and Chronic Obstructive Pulmonary Disease //Pharmacoeconomics. 2001.- Vol. 19 (Suppl.2).- P. 1-6

429. Verberne A.A.P.H., Frost C., Boggard J.M. One year treatment with salmeterol, compared to inhaled corticosteroid in children with mild to moderate asthma. //Am.Rev.Resp.Care.Med.- 1996. -Vol.153.- A408

430. Vercelli D., Jabara H.H., Arai H.H. et al. Induction of human IgE synthesis requires interlukin4 and T-B cell interactions involving the T-cell receptor CD3 complex and MHC class II antigens. // J.Exp. Med. 1989.-Vol. 169. -P. 1295-307

431. Verleden G.M., Pype J.L., Demedts MG. Furosemide and bumetanide but not nedocromil sodium, modulate non-adrenergic relaxation in guinea-pig trachea in-vitro. //Am J Respir Crit Care Med -1994-Vol.l49 -P. 139-44.

432. Vrugt B., Shute J., Aalbers R. et all. Interleukin-8 and its auto antibodies in severe asthma. // Am J Respir Crit Care Med 1994:-- 149A;- p.963 (abstract).

433. Vrugt B., Wilson S., Underwood J.M. et al. Increased expression of interleukin-2 receptor in peripheral blood and bronchial biopsies from severe asthmatics.// Eur Respir j . 1994- Vol.7. -P. 2395 (abstract).

434. Walker C., Virchow J.C., Blaser K. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma.// J Immunol 1991- Vol.136 — P. 1829-35.

435. Walley T., Barton S. A purchaser perspective of managing new drugs: intreferon beta at a case study. //BMJ 1995. Vol. 311. - P. 796-799

436. Walsh L J., Trinchieri G., Waldorf H.A. et al. Human dermal mast cells contain and release tumour necrosis factor a which induces leukocyte adhesion molecule-1.// Proc Natl Acad Sci USA 1991.-Vol.86.-P. 4220-4.

437. Warner K.E., Luce B.R. Cost-benefit and cost-effectiveness analysis in health care: principles, practice, and potential. Ann Arbor, MI: Health Administration press, 1982

438. Warringa R., Mengelers H., Maikoe T. et al. Inhibition of cytokine-primed eosinophil chemotaxis by nedocromil sodium.// J Allergy Clin Immunol -1993- Vol.91 -P. 802-9

439. Weiss K.B., Gergen P.J., Hodgson T.A. An economic evaluation of asthma in the United States. //N Engl J Med 1992. - Vol. 326 (13).- P. 862-6

440. Wenzel S.E, Larsen G., Johnston K. et al. Elevated levels of leukotrience C in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge.// Am Rev Respir Dis -1990,- Vol.142.-P. 112-9.

441. Wenzel S.E., Trudeau JB., Kaminsky DA. et al. Effect of 5-lipoxygenase inhibition on broncho-constriction and airway inflammation in nocturnal asthma.// Am J.Respir Crit Care Med -1995 Vol. 152(3). - P. 897-905.

442. Wickman M., Nordvall S.L., Perchagen G. Risk factors in early childhood for sensitisation in airborne allergens.//Pediatr.Allergy. Immunol.-1992.-Vol.3. P. 128-133

443. Wilding P., Clark M., Coon J. T. et al. Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study. //Br. Med. J. -1997. Vol. 314.- P. 1441-1446.

444. Williams H., McNicol K.N. Prevalence, natural history and relationship of wheezy bronchitis and asthma in children// Br. Med. J. -1969. -Vol. 4. -P. 321-325

445. Williams J. Efficacy and ease of use of the fluticasone propionate multi-dose powder inhaler compared with the budesonide reservoir powder device in asthmatic children.?//Eur. Respir. J. 1995. - Vol. 8(Suppl. 19).-469s.

446. Wilson J.W., Djukanovic R, Howarth P.H., Holgate S.T. Lymphocyte activation in bronchoalveolar lavage and peripheral blood in atopic asthma.// Am Rev Respir Dis -1992.- Vol.145-P. 958-60.

447. Wilson R., Read R., Cole P. Interaction of Haemophilus influenzae with mucus, cilia, and respiratory epithelium. //J Infect Dis 1992 - 165 Suppl 1 - SI00-2.

448. Woolcock A., Lundback B., Ringdal N. et al Comparison of addition of salmeterol of inhaled steroid with doubling of the dose of inhaled corticosteroids.//Am J Respir Crit Care Med-1996-Vol.153.-P. 1481-1488

449. Woolcock A.J. In: Asthma & Rhinitis. Vol. I. (Blackwell), Ed. W. Busse & S.T. Holgate. 1995.- P. 1364-1379

450. World Bank. Country profile. Russia. (Internet) 13.02.01 http://devdata.worldbank.org/external/dgprofile.asp?rmdk=82514«few=0«feL=E

451. Wrighton C. J., Hofer-Warbinek R., Moll T. et al. Inhibition of endothelial cell activation by adenovirus-mediated expression of, an inhibitor of transcription factor NF-B. //J. Exp. Med. 1996. - Vol. 183.- P. 1013-1022

452. Yan K., Salome C., Woodcock A.J. Rapid method for measurment of bronchial responsiveness// Thorax- 1983. -Vol.38. -P. 523-526

453. Zannotti E., Rampula C. Exercize-induced asthma. //Eur. Respir. Rev. -1993.- Vol. 3.-P. 358-361

454. Zeiger R.S., Heller S., Mellon M.H. et al. Fascinated referral to asthma specialist reduce relapses in asthma emergency room visits. //J Allergy Clin Immunol 1991. -Vol. 87 (6).-P. 1160-8

455. Zetterstrom O., Buhl R., Meilern H., Andersson F. The whole story: treatment outcomes with Symbicort. //Resp Med 2002. - Vol. 96 (Suppl A).- S29-35

456. Zhang K., Clark E., Saxon A. CD40 stimulation provides an IFN-independent and IL4-dependent differentiation signal directly to human B cells for IgE production. //J.Immunol.-1991.-Vol. 146.-P. 1836-1842

457. Ziesche R., Block L.H. The lung as an immunologic organ//Wien Klin Wochenschr Suppl -1999.- Vol 1,- P. 1-5.

458. Zitt N., Jeenan J. Clinical experience study with Nedocromil sodium: results of cough, nighttime asthma, and day missed from work and school.// Ann.Allergy.- 1994. -Vol.96 P.62